IL91941A - Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a) - Google Patents

Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)

Info

Publication number: IL91941A
Authority: IL; Israel
Prior art keywords: formula; compound; butyl; ester; chloro
Prior art date: 1988-10-13

Application number

IL9194189A

Other languages

English (en)

Hebrew (he)

Other versions

IL91941A0 (en

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-13

Filing date

1989-10-11

Publication date

1994-10-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26945992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL91941(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-10-11 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-06-10 Publication of IL91941A0 publication Critical patent/IL91941A0/xx

1994-10-21 Publication of IL91941A publication Critical patent/IL91941A/en

Links

ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 34
238000002360 preparation method Methods 0.000 title claims description 20
239000000543 intermediate Substances 0.000 title description 9
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 title description 3
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical class C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 214
238000006243 chemical reaction Methods 0.000 claims abstract description 31
239000002253 acid Substances 0.000 claims abstract description 29
150000003839 salts Chemical group 0.000 claims abstract description 29
125000000422 delta-lactone group Chemical group 0.000 claims abstract description 10
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 7
125000004185 ester group Chemical group 0.000 claims abstract description 7
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
-1 cyclic boronate compound Chemical class 0.000 claims description 101
238000000034 method Methods 0.000 claims description 89
230000008569 process Effects 0.000 claims description 75
239000001257 hydrogen Substances 0.000 claims description 73
229910052739 hydrogen Inorganic materials 0.000 claims description 73
239000000203 mixture Substances 0.000 claims description 67
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 56
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 52
125000001153 fluoro group Chemical group F* 0.000 claims description 50
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 50
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
239000012429 reaction media Substances 0.000 claims description 35
125000001309 chloro group Chemical group Cl* 0.000 claims description 34
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
125000004432 carbon atom Chemical group C* 0.000 claims description 27
150000002148 esters Chemical group 0.000 claims description 25
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 25
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 25
239000002585 base Substances 0.000 claims description 24
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 22
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 22
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 20
229910052799 carbon Inorganic materials 0.000 claims description 19
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 17
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 16
239000003153 chemical reaction reagent Substances 0.000 claims description 14
230000003301 hydrolyzing effect Effects 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
239000012279 sodium borohydride Substances 0.000 claims description 11
229910000033 sodium borohydride Inorganic materials 0.000 claims description 11
125000001246 bromo group Chemical group Br* 0.000 claims description 10
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
239000007858 starting material Substances 0.000 claims description 8
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 7
150000001450 anions Chemical class 0.000 claims description 7
229910052796 boron Inorganic materials 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 5
159000000000 sodium salts Chemical group 0.000 claims description 5
238000011916 stereoselective reduction Methods 0.000 claims description 5
OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 claims description 4
239000012359 Methanesulfonyl chloride Substances 0.000 claims description 4
GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 claims description 4
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 claims description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 4
230000003472 neutralizing effect Effects 0.000 claims description 4
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
239000002243 precursor Substances 0.000 claims 1
241000845077 Iare Species 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 81
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
150000002431 hydrogen Chemical class 0.000 description 54
239000000243 solution Substances 0.000 description 51
239000000047 product Substances 0.000 description 47
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
239000011541 reaction mixture Substances 0.000 description 32
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 31
239000000376 reactant Substances 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
239000002904 solvent Substances 0.000 description 20
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 16
JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 16
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 15
239000003921 oil Substances 0.000 description 15
239000012044 organic layer Substances 0.000 description 15
229910000029 sodium carbonate Inorganic materials 0.000 description 14
238000004821 distillation Methods 0.000 description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
238000010992 reflux Methods 0.000 description 12
UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 11
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
238000001816 cooling Methods 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
239000012071 phase Substances 0.000 description 10
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
230000009467 reduction Effects 0.000 description 9
238000006722 reduction reaction Methods 0.000 description 9
238000003756 stirring Methods 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 8
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 8
239000007788 liquid Substances 0.000 description 8
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
239000012298 atmosphere Substances 0.000 description 7
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 7
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
239000012267 brine Substances 0.000 description 7
239000008367 deionised water Substances 0.000 description 7
229910021641 deionized water Inorganic materials 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
239000000126 substance Substances 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 6
239000007795 chemical reaction product Substances 0.000 description 6
125000004122 cyclic group Chemical group 0.000 description 6
239000012065 filter cake Substances 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
229910000085 borane Inorganic materials 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
238000001914 filtration Methods 0.000 description 5
125000000468 ketone group Chemical group 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
239000002002 slurry Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
YLMOTKLYENPQLK-VMPITWQZSA-N (e)-3-(n-methylanilino)prop-2-enal Chemical compound O=C/C=C/N(C)C1=CC=CC=C1 YLMOTKLYENPQLK-VMPITWQZSA-N 0.000 description 4
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
238000010791 quenching Methods 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
229960001922 sodium perborate Drugs 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 4
230000000707 stereoselective effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
239000003518 caustics Substances 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
150000004702 methyl esters Chemical group 0.000 description 3
150000002978 peroxides Chemical class 0.000 description 3
235000019814 powdered cellulose Nutrition 0.000 description 3
229920003124 powdered cellulose Polymers 0.000 description 3
GIZSHQYTTBQKOQ-UHFFFAOYSA-N threo-Syringoylglycerol Chemical compound COC1=CC(C(O)C(O)CO)=CC(OC)=C1O GIZSHQYTTBQKOQ-UHFFFAOYSA-N 0.000 description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
125000001207 fluorophenyl group Chemical group 0.000 description 2
229910052733 gallium Inorganic materials 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000002440 hydroxy compounds Chemical class 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
208000020346 hyperlipoproteinemia Diseases 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000010265 sodium sulphite Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000003944 tolyl group Chemical group 0.000 description 2
JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
ZDZJOIIBECYKAJ-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-propan-2-ylindole Chemical compound C12=CC=CC=C2N(C(C)C)C=C1C1=CC=C(F)C=C1 ZDZJOIIBECYKAJ-UHFFFAOYSA-N 0.000 description 1
XLPGQDGLAUEQDH-UHFFFAOYSA-N 3-(n-methylanilino)prop-2-enal;hydrochloride Chemical compound Cl.O=CC=CN(C)C1=CC=CC=C1 XLPGQDGLAUEQDH-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000034809 Product contamination Diseases 0.000 description 1
JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
238000001514 detection method Methods 0.000 description 1
RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
125000005059 halophenyl group Chemical group 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
RWNJOXUVHRXHSD-UHFFFAOYSA-N hept-6-enoic acid Chemical compound OC(=O)CCCCC=C RWNJOXUVHRXHSD-UHFFFAOYSA-N 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
229940057061 mevalonolactone Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
125000006606 n-butoxy group Chemical group 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000002912 oxalic acid derivatives Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
102200014657 rs121434437 Human genes 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
239000011269 tar Substances 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
239000002351 wastewater Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Obesity (AREA)
Veterinary Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrane Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)

IL9194189A 1988-10-13 1989-10-11 Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a) IL91941A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25747588A	1988-10-13	1988-10-13
US35553189A	1989-05-22	1989-05-22

Publications (2)

Publication Number	Publication Date
IL91941A0 IL91941A0 (en)	1990-06-10
IL91941A true IL91941A (en)	1994-10-21

Family

ID=26945992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9194189A IL91941A (en)	1988-10-13	1989-10-11	Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)

Country Status (24)

Country	Link
EP (2)	EP0363934B1 (ro)
JP (1)	JP2853227B2 (ro)
KR (1)	KR0162656B1 (ro)
AT (1)	ATE99281T1 (ro)
AU (1)	AU636122B2 (ro)
BG (1)	BG60555B1 (ro)
CA (1)	CA2000553C (ro)
CZ (1)	CZ283316B6 (ro)
DE (1)	DE68911834T2 (ro)
DK (1)	DK175073B1 (ro)
ES (1)	ES2060712T3 (ro)
FI (1)	FI98063C (ro)
HK (1)	HK49496A (ro)
HU (1)	HU207993B (ro)
IE (2)	IE940109L (ro)
IL (1)	IL91941A (ro)
MY (1)	MY105067A (ro)
NO (1)	NO174623C (ro)
NZ (1)	NZ230973A (ro)
RO (1)	RO109732B1 (ro)
SG (1)	SG139553A1 (ro)
SK (1)	SK280845B6 (ro)
WO (1)	WO1990003962A1 (ro)
YU (1)	YU48466B (ro)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5290946A (en) *	1988-10-13	1994-03-01	Sandoz Ltd.	Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) *	1988-10-13	1992-06-02	Sandoz Ltd.	Processes for the synthesis of 3-disubstituted aminoacroleins
JPH03184961A (ja) *	1989-10-10	1991-08-12	Glaxo Group Ltd	化合物
DE4424525A1 (de) *	1994-07-12	1995-01-26	Elmar Meyer	Dauermagnet-Kolbenmotor
GT199800127A (es)	1997-08-29	2000-02-01		Combinaciones terapeuticas.
DK1216038T3 (da)	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
CN1217930C (zh)	2000-05-26	2005-09-07	西巴特殊化学品控股有限公司	吲哚衍生物的制备方法和该方法的中间体
US7777006B2 (en)	2002-12-31	2010-08-17	Csl Behring L.L.C.	Method for purification of alpha-1-antitrypsin
EP1623976A4 (en) *	2003-04-24	2008-07-30	Daicel Chem	METHOD FOR SEPARATING OPTICALLY ACTIVE DIHYDROXYPHIC ACID ESTERS
US7368468B2 (en)	2003-06-18	2008-05-06	Teva Pharmaceutical Industries Ltd.	Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en)	2003-06-18	2008-05-06	Teva Pharmaceutical Industries Ltd.	Process for the preparation of fluvastatin sodium crystal from XIV
JP4037898B2 (ja)	2003-06-18	2008-01-23	テバファーマシューティカルインダストリーズリミティド	フルバスタチンナトリウム結晶形ｘｉｖ、ｌｘｘｉｉｉ、ｌｘｘｉｘ、ｌｘｘｘ及びｘｘｘｖｉｉ型、それらの調製方法、それらを含有する組成物及びそれらの使用方法
JP2007512347A (ja)	2003-11-26	2007-05-17	デューク・ユニバーシティー	緑内障を予防するかまたは治療する方法
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
US20060211752A1 (en)	2004-03-16	2006-09-21	Kohn Leonard D	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
ATE431818T1 (de)	2006-04-20	2009-06-15	Italiana Sint Spa	Verfahren zur herstellung von fluvastatin-natrium
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en)	2008-12-19	2013-10-16	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CN104902892A (zh)	2012-02-02	2015-09-09	悉尼大学	泪液膜稳定性的改进
EP2986599A1 (en)	2013-04-17	2016-02-24	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
BR112021013807A2 (pt)	2019-01-18	2021-11-30	Astrazeneca Ab	Inibidores de pcsk9 e seus métodos de uso
WO2025168652A1 (en)	2024-02-05	2025-08-14	Astrazeneca Ab	Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
TW202602886A (zh)	2024-03-20	2026-01-16	瑞典商阿斯特捷利康公司	Ｐｃｓｋ９抑制劑及其使用方法
TW202602866A (zh)	2024-03-20	2026-01-16	瑞典商阿斯特捷利康公司	Ｐｃｓｋ９抑制劑及其使用方法
TW202539678A (zh)	2024-03-20	2025-10-16	瑞典商阿斯特捷利康公司	Ｐｃｓｋ９抑制劑及其使用方法
WO2025238159A1 (en)	2024-05-16	2025-11-20	Astrazeneca Ab	Combination therapy comprising azd0780 and ezetimibe

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB945536A (en) *	1961-09-08	1964-01-02	Istituto Chemioterapico	Method of preparing ª -amino-acroleins
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) *	1982-11-22	1991-12-30	Sandoz Ag	Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4571428A (en) *	1983-07-08	1986-02-18	Sandoz, Inc.	6-Substituted-4-hydroxy-tetrahydropyran-2-ones
US4650890A (en) *	1984-04-03	1987-03-17	Sandoz Corp.	Preparation of olefinic compounds and intermediates thereof
ATE62906T1 (de) *	1984-06-22	1991-05-15	Sandoz Ag	Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
ATE60571T1 (de) *	1984-12-04	1991-02-15	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
EP0244364A3 (en) *	1986-04-30	1992-04-01	Sandoz Ag	Preparation of olefinic compounds
NZ221717A (en) *	1986-09-10	1990-08-28	Sandoz Ltd	Azaindole and indolizine derivatives and pharmaceutical compositions

1989
- 1989-10-11 JP JP1510605A patent/JP2853227B2/ja not_active Expired - Lifetime
- 1989-10-11 AU AU43448/89A patent/AU636122B2/en not_active Expired
- 1989-10-11 IL IL9194189A patent/IL91941A/en not_active IP Right Cessation
- 1989-10-11 WO PCT/EP1989/001201 patent/WO1990003962A1/en not_active Ceased
- 1989-10-11 KR KR1019900701243A patent/KR0162656B1/ko not_active Expired - Lifetime
- 1989-10-11 MY MYPI89001403A patent/MY105067A/en unknown
- 1989-10-11 SG SG200602066-3A patent/SG139553A1/en unknown
- 1989-10-11 IE IE940109A patent/IE940109L/xx unknown
- 1989-10-11 EP EP89118906A patent/EP0363934B1/en not_active Expired - Lifetime
- 1989-10-11 HU HU896048A patent/HU207993B/hu unknown
- 1989-10-11 ES ES89118906T patent/ES2060712T3/es not_active Expired - Lifetime
- 1989-10-11 DE DE68911834T patent/DE68911834T2/de not_active Expired - Lifetime
- 1989-10-11 AT AT89118906T patent/ATE99281T1/de not_active IP Right Cessation
- 1989-10-11 EP EP19930106005 patent/EP0562643A3/en not_active Ceased
- 1989-10-11 IE IE327789A patent/IE63477B1/en not_active IP Right Cessation
- 1989-10-11 YU YU197389A patent/YU48466B/sh unknown
- 1989-10-11 NZ NZ230973A patent/NZ230973A/xx unknown
- 1989-10-11 RO RO145326A patent/RO109732B1/ro unknown
- 1989-10-12 SK SK5797-89A patent/SK280845B6/sk unknown
- 1989-10-12 CZ CS895797A patent/CZ283316B6/cs not_active IP Right Cessation
- 1989-10-12 CA CA002000553A patent/CA2000553C/en not_active Expired - Lifetime
1990
- 1990-06-07 BG BG92179A patent/BG60555B1/bg unknown
- 1990-06-12 NO NO902598A patent/NO174623C/no unknown
- 1990-06-12 FI FI902935A patent/FI98063C/fi active IP Right Grant
- 1990-06-13 DK DK199001446A patent/DK175073B1/da not_active IP Right Cessation
1996
- 1996-03-21 HK HK49496A patent/HK49496A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
IE63477B1 (en)	1995-04-19
KR0162656B1 (ko)	1999-01-15
ATE99281T1 (de)	1994-01-15
NO902598D0 (no)	1990-06-12
YU197389A (en)	1990-12-31
DK175073B1 (da)	2004-05-24
CZ579789A3 (en)	1997-11-12
JP2853227B2 (ja)	1999-02-03
HK49496A (en)	1996-03-29
EP0562643A2 (en)	1993-09-29
MY105067A (en)	1994-07-30
FI98063B (fi)	1996-12-31
KR900701723A (ko)	1990-12-04
JPH03501735A (ja)	1991-04-18
IL91941A0 (en)	1990-06-10
EP0363934A1 (en)	1990-04-18
NO174623C (no)	1994-06-08
NO174623B (no)	1994-02-28
HUT53860A (en)	1990-12-28
DK144690D0 (da)	1990-06-13
DE68911834D1 (de)	1994-02-10
DE68911834T2 (de)	1994-06-23
EP0363934B1 (en)	1993-12-29
SK579789A3 (en)	2000-08-14
CZ283316B6 (cs)	1998-02-18
HU896048D0 (en)	1990-11-28
EP0562643A3 (en)	1994-05-18
SK280845B6 (sk)	2000-08-14
CA2000553C (en)	2001-12-04
IE940109L (en)	1990-04-13
AU4344889A (en)	1990-05-01
IE893277L (en)	1990-04-13
FI902935A0 (fi)	1990-06-12
RO109732B1 (ro)	1995-05-30
BG60555B1 (en)	1995-08-28
CA2000553A1 (en)	1990-04-13
ES2060712T3 (es)	1994-12-01
FI98063C (fi)	1997-04-10
NZ230973A (en)	1993-03-26
BG92179A (bg)	1993-12-24
AU636122B2 (en)	1993-04-22
DK144690A (da)	1990-06-13
YU48466B (sh)	1998-08-14
WO1990003962A1 (en)	1990-04-19
NO902598L (no)	1990-08-07
SG139553A1 (en)	2008-02-29
HU207993B (en)	1993-07-28

Legal Events

Date	Code	Title
1997-11-20	HC	Change of name of proprietor(s)
2000-02-17	KB	Patent renewed
2003-12-10	KB	Patent renewed
2007-12-03	KB	Patent renewed
2010-05-31	EXP	Patent expired

Publication	Publication Date	Title
IL91941A (en)	1994-10-21	Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)
US5189164A (en)	1993-02-23	Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
KR960009434B1 (ko)	1996-07-19	3-데메틸메발론산 유도체, 이의 제조방법 및 중간체
Arai et al.	1998	Asymmetric synthesis of α, β-epoxysulfones under phase-transfer catalyzed Darzens reaction
JP3233403B2 (ja)	2001-11-26	光学活性な中間体および該製造法
WO1995011898A1 (en)	1995-05-04	Condensed pyridine type mevalonolactone intermediate and process for its production
WO1990003973A1 (en)	1990-04-19	Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
JPH02188571A (ja)	1990-07-24	化合物
EP0312269A2 (en)	1989-04-19	3,5-Dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
AU693588B2 (en)	1998-07-02	Novel process for the preparation of diisopinocampheylchloroborane
Yusufoglu et al.	1986	Enantioselective synthesis and absolute configuration of both enantiomers of endo-brevicomin
JPH0592963A (ja)	1993-04-16	Ｐａｆ拮抗剤として有用な２，５−ジアリールテトラヒドロフラン類及びその類縁体の製造方法
CN1017892B (zh)	1992-08-19	4，5-二取代γ-丁内酰胺纯对映体的制备方法
RU2051907C1 (ru)	1996-01-10	Способ получения 7-замещенной гептен-6-овой кислоты
CN101014714B (zh)	2012-05-23	产生二芳基环烷基衍生物的方法
Uematsu et al.	1984	A Novel Class of Fungicides: Synthesis of (R)-and (S-) α-Benzylidene-γ-methyl-γ-butyrolactones
JP3006748B2 (ja)	2000-02-07	光学活性な７−置換ピリジル−３，５−ジヒドロキシ−ヘプト−６−エン酸エステル誘導体の製法
HRP940993A2 (en)	1997-06-30	Process for the preparation of 7-substituted hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof
JP2974181B2 (ja)	1999-11-08	シクロブタノールの新規な製造法
SA90100111B1 (ar)	2005-04-17	طريقة لتحضير 7- مستبدل- حمض هبت-6- ينويك وحمض هبتانويك ومشتقات منها
PT91980B (pt)	1995-05-31	Processo para a preparacao de acidos hept-6-enoicos e heptanoicos substituidos na posicao 7 e seus derivados e produtos intermediarios